At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years
- ✓BMI ≥30 kg/m²
- ✓Enrolled in Cleveland Clinic Employee Health Plan with expected coverage for study duration
- ✓Informed consent obtained before any study-related activities
- ✕Contraindications to all FDA-approved medications for chronic weight management
- ✕Weight loss medication use within 90 days before screening
- ✕Prior or current participation in Cleveland Clinic's Integrated Medical Weight Management Program
- ✕Bariatric surgery or minimally-invasive weight loss devices not removed within 1 year prior to screening
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity - a Pragmatic Randomized Trial
In Brief
A Phase 4 clinical trial evaluating Weight Management Program (WMP) and Medication for chronic weight management (Rx) for Obesity. Completed, enrolled 200 participants across 1 site.
Detailed Summary
Researchers are doing this study to compare the effects of drugs approved for long-term weight loss combined with an employer-based weight management program with the effects of the weight management program without drugs for weight loss. If participants agree to be in this study, they will join the Cleveland Clinic Integrated Medical Weight Management Program (WMP). Participants will be assigned by chance (like flipping a coin) to one of two treatment groups: A) Group 1: Cleveland Clinic Integrated Medical WMP + medication for long-term weight loss. B) Group 2: Cleveland Clinic Integrated Medical WMP without medication for weight loss. Participants have an equal chance of being in either of the treatment groups. The total study duration for the individual participants will be approximately one year.
Study Details
Timeline
Interventions
As part of usual care, participants will: 1) Discuss and choose one of three diet options: protein-sparing modified fast, Mediterranean, or meal replacement. 2) Be referred to a nutritionist appointment. 3) Initiate a series of twelve monthly study visits in the context of shared medical appointments (SMAs) covering nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress. 4) Be referred to an exercise physiologist for a personalized physical activity program. 5) If assessed relevant by the study clinician, be referred to a mental health specialist and/or sleep clinic.
Following listed 5 drugs will be administered as prescribed by the study doctor: 1\) Orlistat (Xenical® pills, per os \[p.o.; by mouth\]). 2) Lorcaserin or lorcaserin extended-release (Belviq®/Belviq XR® pills, p.o.). 3) Phentermine/topiramate extended-release (Qsymia® pills, p.o.). 4) Naltrexone/bupropion extended-release (Contrave® pills, p.o.). 5) Liraglutide 3.0 mg (Saxenda® injections, subcutaneously \[under the skin\]).